Walpar Nutritions Limited (NSE:WALPAR)

Market Cap	413.18M
Revenue (ttm)	719.60M
Net Income (ttm)	23.24M
Shares Out	9.39M
EPS (ttm)	2.48
PE Ratio	17.77
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,000
Average Volume	10,500
Open	45.10
Previous Close	46.35
Day's Range	45.10 - 45.10
52-Week Range	37.85 - 53.30
Beta	-0.60
RSI	54.95
Earnings Date	Nov 9, 2025

About Walpar Nutritions

Walpar Nutritions Limited manufactures and trades pharmaceutical, nutraceutical, herbal, and ayurvedic commodities in India. The company offers G-Flora, a probiotic blend for gut health and immunity; Inosia-F, an inositol supplement; Inovam Plus, a multivitamin; Ironica-CR, controlled-release iron supplement; Myobest, muscle support formula; Ovality, ovarian health support; Ovanyx-F, a female reproductive health supplement; Ovacon-F, women's fertility support; PCOS Care Forte, a PCOS support; Procive-F, female fertility enhancement supplement; ...

• Industry: Pharmaceutical Preparations
• Founded: 2009
• Country: India
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: WALPAR

Financial Performance

In 2024, Walpar Nutritions's revenue was 719.60 million, an increase of 14.93% compared to the previous year's 626.13 million. Earnings were 23.24 million, an increase of 46.92%.